Compare Cassava Sciences Inc (FLNA) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Vanguard Total World Stock Index Fund ETF trades at $159.86 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 2581.2× Cassava Sciences Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| FLNA | VT | |
|---|---|---|
Market Cap | $39.40M | $101.70B |
Volume | 759,018 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $162.39 |
52-Week Low | $0.68 | $134.19 |
Typical Hold Time | 37 Days | 53 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Vanguard Total World Stock ETF (VT) trades at $159.84, up 0.13% with a bearish technical signal from moving averages. The ETF provides exposure to over 9,700 global stocks with a 0.06% expense ratio, though key financial ratios remain unavailable. Recent news highlights VT's diversification benefits and competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF.
VT offers broad global diversification but faces headwinds from technical bearish signals and expense ratio competition. The outlook remains neutral with institutional interest mixed; risks include market volatility and geopolitical factors. Long-term investors may value its comprehensive market coverage despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
